These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 25512414)

  • 41. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
    Jamal JA; Udy AA; Lipman J; Roberts JA
    Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains.
    Adnan S; Li JX; Wallis SC; Rudd M; Jarrett P; Paterson DL; Lipman J; Udy AA; Roberts JA
    Int J Antimicrob Agents; 2013 Jul; 42(1):90-3. PubMed ID: 23590897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.
    Roberts JA; Abdul-Aziz MH; Lipman J; Mouton JW; Vinks AA; Felton TW; Hope WW; Farkas A; Neely MN; Schentag JJ; Drusano G; Frey OR; Theuretzbacher U; Kuti JL;
    Lancet Infect Dis; 2014 Jun; 14(6):498-509. PubMed ID: 24768475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?
    Roberts JA; Paul SK; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
    Clin Infect Dis; 2014 Apr; 58(8):1072-83. PubMed ID: 24429437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?
    Wong G; Briscoe S; Adnan S; McWhinney B; Ungerer J; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6165-70. PubMed ID: 24080664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection.
    Briscoe SE; McWhinney BC; Lipman J; Roberts JA; Ungerer JP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Oct; 907():178-84. PubMed ID: 23026224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.
    Bulitta JB; Landersdorfer CB; Forrest A; Brown SV; Neely MN; Tsuji BT; Louie A
    Curr Pharm Biotechnol; 2011 Dec; 12(12):2044-61. PubMed ID: 21554212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
    Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
    J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimization of meropenem dosage in the critically ill population based on renal function.
    Crandon JL; Ariano RE; Zelenitsky SA; Nicasio AM; Kuti JL; Nicolau DP
    Intensive Care Med; 2011 Apr; 37(4):632-8. PubMed ID: 21136037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetics of meropenem in burn patients.
    Doh K; Woo H; Hur J; Yim H; Kim J; Chae H; Han S; Yim DS
    J Antimicrob Chemother; 2010 Nov; 65(11):2428-35. PubMed ID: 20817742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
    Roberts JA; Ulldemolins M; Roberts MS; McWhinney B; Ungerer J; Paterson DL; Lipman J
    Int J Antimicrob Agents; 2010 Oct; 36(4):332-9. PubMed ID: 20685085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection.
    McWhinney BC; Wallis SC; Hillister T; Roberts JA; Lipman J; Ungerer JP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jul; 878(22):2039-43. PubMed ID: 20561826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibiotic resistance--what's dosing got to do with it?
    Roberts JA; Kruger P; Paterson DL; Lipman J
    Crit Care Med; 2008 Aug; 36(8):2433-40. PubMed ID: 18596628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meropenem: a review of its use in the treatment of serious bacterial infections.
    Baldwin CM; Lyseng-Williamson KA; Keam SJ
    Drugs; 2008; 68(6):803-38. PubMed ID: 18416587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
    Li C; Du X; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2007 May; 51(5):1725-30. PubMed ID: 17307978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
    Li C; Kuti JL; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.